MiNK Therapeutics (NASDAQ:INKT) Rating Increased to Hold at Zacks Research

Key Points

• MiNK Therapeutics has been upgraded from a "strong sell" to a "hold" rating by Zacks Research, indicating a shift in analysts' outlook towards the stock.
• The stock price target consensus for MiNK Therapeutics is currently set at $37.50, showing positive expectations despite mixed ratings from multiple analysts.
• MiNK Therapeutics reported a loss of ($1.06) EPS for the last quarter, which was below the consensus estimate, raising concerns about its financial performance.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Monday,Zacks.com reports.

Several other equities analysts also recently weighed in on the stock. William Blair downgraded shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. B. Riley raised shares of MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. HC Wainwright raised MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective for the company in a report on Friday, August 15th. Finally, Wall Street Zen lowered MiNK Therapeutics to a "strong sell" rating in a report on Saturday, August 23rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.50.

MiNK Therapeutics Trading Down 0.4%

NASDAQ INKT opened at $14.81 on Monday. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $76.00. The company has a fifty day simple moving average of $14.72 and a two-hundred day simple moving average of $12.05. The stock has a market cap of $66.92 million, a P/E ratio of -5.14 and a beta of 0.33.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.51). As a group, sell-side analysts forecast that MiNK Therapeutics will post -2.75 earnings per share for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.